Parikh Nehal A, Lasky Robert E, Kennedy Kathleen A, Moya Fernando R, Hochhauser Leo, Romo Seferino, Tyson Jon E
Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Texas Medical School at Houston, Houston, TX 77030, USA.
Pediatrics. 2007 Feb;119(2):265-72. doi: 10.1542/peds.2006-1354.
Our goal was to relate postnatal dexamethasone therapy in extremely low birth weight infants (birth weight of < or = 1000 g) to their total and regional brain volumes, as measured by volumetric MRI performed at term-equivalent age.
Among 53 extremely low birth weight infants discharged between June 1 and December 31, 2003, 41 had high-quality MRI studies; 30 of those infants had not received postnatal steroid treatment and 11 had received dexamethasone, all after postnatal age of 28 days, for a mean duration of 6.8 days and a mean cumulative dose of 2.8 mg/kg. Anatomic brain MRI scans obtained at 39.5 weeks (mean) postmenstrual age were segmented by using semiautomated and manual, pretested, scoring algorithms to generate three-dimensional cerebral component volumes. Volumes were adjusted according to postmenstrual age at MRI.
After controlling for postmenstrual age at MRI, we observed a 10.2% smaller total cerebral tissue volume in the dexamethasone-treated group, compared with the untreated group. Cortical tissue volume was 8.7% smaller in the treated infants, compared with untreated infants. Regional volume analysis revealed a 20.6% smaller cerebellum and a 19.9% reduction in subcortical gray matter in the dexamethasone-treated infants, compared with untreated infants. In a series of regression analyses, the reductions in total cerebral tissue, subcortical gray matter, and cerebellar volumes associated with dexamethasone administration remained significant after controlling not only for postmenstrual age but also for bronchopulmonary dysplasia and birth weight.
We identified smaller total and regional cerebral tissue volumes in extremely low birth weight infants treated with relatively conservative regimens of dexamethasone. These volume deficits may be the structural antecedents of neuromotor and cognitive abnormalities reported after postnatal dexamethasone treatment.
我们的目标是将极低出生体重儿(出生体重≤1000克)出生后接受地塞米松治疗的情况,与通过足月等效年龄时进行的容积磁共振成像(MRI)测量的全脑和局部脑容量联系起来。
在2003年6月1日至12月31日出院的53例极低出生体重儿中,41例进行了高质量的MRI研究;其中30例婴儿未接受出生后类固醇治疗,11例接受了地塞米松治疗,均在出生后28天之后开始,平均持续时间为6.8天,平均累积剂量为2.8毫克/千克。在月经龄39.5周(平均)时获得的解剖学脑MRI扫描,通过使用经过预测试的半自动和手动评分算法进行分割,以生成三维脑成分体积。根据MRI时的月经龄对体积进行调整。
在控制了MRI时的月经龄后,我们观察到,与未治疗组相比,地塞米松治疗组的全脑组织体积小10.2%。与未治疗的婴儿相比,治疗组婴儿的皮质组织体积小8.7%。局部体积分析显示,与未治疗的婴儿相比,地塞米松治疗组婴儿的小脑体积小20.6%,皮质下灰质减少19.9%。在一系列回归分析中,不仅在控制月经龄,而且在控制支气管肺发育不良和出生体重后,与地塞米松给药相关的全脑组织、皮质下灰质和小脑体积的减少仍然显著。
我们发现,接受相对保守方案地塞米松治疗的极低出生体重儿,其全脑和局部脑组织体积较小。这些体积缺陷可能是出生后地塞米松治疗后报告的神经运动和认知异常的结构前体。